InnoVet Inc. said it has begun final pivotal studies in horses ofits IVET-629 immune stimulant to treat chronic equinerespiratory diseases of mixed viral and bacterial origin.
The Boca Raton, Fla., company (NASDAQ:IVET) hopes to file forUSDA marketing approval by Nov. 1, said Jesse Houdeshell,president.InnoVet plans to begin by July 1 pivotal studies of the drug,which stimulates B lymphocytes, to treat lymphomas andmammary tumors in dogs and cats.
InnoVet also plans to develop the drug, with a collaborator, forhuman indications, including solid tumors and viral diseases.The company hopes to file within the next 12 months to beginPhase I studies in lymphomas.
(c) 1997 American Health Consultants. All rights reserved.